ZW-239

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameZW-239

Drug Alias NameZW-239

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD28Anti-CLDN18CD3 T-cell engagers

TargetsT-cell-specific surface glycoprotein CD28Claudin-18 splice variant 2T cell surface glycoprotein CD3

Therapy Area/IndicationsDigestive System Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesZymeworks Inc

China Registration ClassN/A

Develop Information

Active CompaniesZymeworks Inc

Inactive CompaniesN/A

Active IndicationsDigestive System Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A